Simplex Trading, LLC Contrafect Corp Transaction History

Simplex Trading, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 02, 2023	SELL	$0.09 - $0.19 $74 - $157	-831 Reduced 4.26%	18,676 $1,000
Q3 2022 Nov 04, 2022	BUY	$0.18 - $3.51 $1,149 - $22,407	6,384 Added 48.65%	19,507 $3,000
Q2 2022 Aug 03, 2022	BUY	$2.79 - $4.45 $36,613 - $58,397	13,123 New	13,123 $40,000
Q1 2022 May 02, 2022	SELL	$2.26 - $3.84 $451 - $768	-200 Closed	0 $0
Q4 2021 Feb 23, 2022	BUY	$2.47 - $4.14 $494 - $827	200 New	200 $0

Q2 2021 Aug 12, 2021	SELL	$3.58 - $4.9 $53,535 - $73,274	-14,954 Closed	0 $0
Q1 2021 Apr 26, 2021	BUY	$4.46 - $6.68 $15,306 - $22,925	3,432 Added 29.79%	14,954 $71,000
Q4 2020 Feb 02, 2021	BUY	$5.05 - $6.4 $58,186 - $73,740	11,522 New	11,522 $58,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.